{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:55:14Z","timestamp":1794002114023,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,15]],"date-time":"2027-06-15T00:00:00Z","timestamp":1813017600000},"content-version":"am","delay-in-days":287,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K02769"],"award-info":[{"award-number":["25K02769"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.05.025","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:59:40Z","timestamp":1781524780000},"page":"165-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of EVITA with safety in advanced urothelial carcinoma: A multicenter real-world study"],"prefix":"10.1016","volume":"44","author":[{"given":"Keita","family":"Ishimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanao","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotake","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Numakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Habuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0026-4079","authenticated-orcid":false,"given":"Shingo","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.05.025_bib0001","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0002","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/iju.15362","article-title":"Summary of the Clinical Practice Guidelines for upper tract urothelial carcinoma 2023 by the Japanese Urological Association","volume":"31","author":"Mori","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0003","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 Guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0004","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0005","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/iju.70162","article-title":"Response to first-line chemotherapy predicts Response to maintenance avelumab therapy in Japanese patients with advanced urothelial carcinoma","volume":"32","author":"Inoue","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0006","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/iju.70136","article-title":"Real-world outcomes of first-line systematic treatment in locally advanced or metastatic upper urinary tract urothelial carcinoma with renal impairment (YUSHIMA Study)","volume":"32","author":"Kimura","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0007","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/iju.70178","article-title":"Assessing response durability and survival after second-line Pembrolizumab in advanced urothelial carcinoma: a multicenter validation of a risk model","volume":"32","author":"Salah","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0008","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1111\/iju.70241","article-title":"Impact of C-reactive protein kinetics on the prognosis of the patient with metastatic urothelial carcinoma treated with Enfortumab Vedotin","volume":"32","author":"Tsujioka","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0009","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/iju.70113","article-title":"Evaluation of optimal sequential treatment patterns and clinical outcomes in patients with advanced urothelial carcinoma treated with first-line platinum-based chemotherapy: a multicenter collaborative study","volume":"32","author":"Urabe","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0010","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/jjco\/hyaf060","article-title":"Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective study","volume":"55","author":"Urabe","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0011","article-title":"Prognostic nutritional index predicts the prognostic impact of avelumab maintenance therapy in patients with advanced urothelial carcinoma: results from the Chu-shikoku Japan Urological Consortium","author":"Fukuhara","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0012","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0013","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/jjco\/hyaf182","article-title":"Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study","volume":"56","author":"Iwatani","year":"2026","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0014","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10147-024-02672-3","article-title":"Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response","volume":"30","author":"Nagayama","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0015","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/iju.70030","article-title":"Impact of skin adverse events on prognosis in patients with locally advanced or metastatic urothelial carcinoma treated with Enfortumab Vedotin: a real-world multicenter study","volume":"32","author":"Ozaki","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0016","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/jjco\/hyae082","article-title":"Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study","volume":"54","author":"Hayakawa","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/iju.70329","article-title":"Clinical features and risk factors of Enfortumab Vedotin-induced peripheral neuropathy in patients with metastatic urothelial carcinoma: a multicenter retrospective study (YUSHIMA Study)","volume":"33","author":"Soma","year":"2026","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0018","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/jjco\/hyaf049","article-title":"Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma","volume":"55","author":"Minato","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102278","article-title":"Real-world evidence for Enfortumab Vedotin in patients with metastatic urothelial cancer: an Austrian multicentre study","volume":"23","author":"Niedersuess-Beke","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1397692","article-title":"Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database","volume":"15","author":"Yu","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0021","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s10147-025-02873-4","article-title":"First-line treatment options for metastatic urothelial carcinoma: balancing efficacy, safety, and individual values and preferences through shared decision making","volume":"30","author":"Nagumo","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0022","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/iju.15368","article-title":"Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: a multicenter observational study","volume":"31","author":"Fukuokaya","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0023","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/iju.15411","article-title":"Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan","volume":"31","author":"Kita","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0024","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/iju.15437","article-title":"Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data","volume":"31","author":"Uemura","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0025","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/iju.15435","article-title":"Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: a retrospective multicenter study in Japan","volume":"31","author":"Hara","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0026","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/j.eururo.2024.06.022","article-title":"Re: thomas Powles, Begona Perez-Valderrama, Shilpa Gupta, et al. Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial Cancer. N Engl J Med 2024;390:875-88","volume":"86","author":"Grande","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0027","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/iju.70040","article-title":"Real-world analysis of the Enfortumab Vedotin-ineligible criTeriA assessment in treatment-naive patients with locally advanced or metastatic urothelial carcinoma","volume":"32","author":"Miyake","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103725","article-title":"The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria","volume":"9","author":"Apolo","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0029","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-09806-1","article-title":"Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma","volume":"15","author":"Fukushima","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0030","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf333","article-title":"Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey","volume":"30","author":"Grande","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0031","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71284","article-title":"Treatment-related adverse events and associated outcomes in patients with advanced urothelial carcinoma treated with Enfortumab Vedotin: analysis of the UNITE study","volume":"14","author":"Nizam","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.urolonc.2026.05.025_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2026.102501","article-title":"Real-world outcomes of patients with baseline neuropathy and\/or diabetes mellitus receiving Enfortumab Vedotin-based regimens for advanced urothelial carcinoma in the UNITE Database","volume":"24","author":"Jang","year":"2026","journal-title":"Clin Genitourin Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:26:18Z","timestamp":1793802378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1078143926005533"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.025","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of EVITA with safety in advanced urothelial carcinoma: A multicenter real-world study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}